408 related articles for article (PubMed ID: 21256876)
1. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007.
Anh DD; Carlos CC; Thiem DV; Hutagalung Y; Gatchalian S; Bock HL; Smolenov I; Suryakiran PV; Han HH
Vaccine; 2011 Mar; 29(11):2029-36. PubMed ID: 21256876
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe.
Vesikari T; Karvonen A; Prymula R; Schuster V; Tejedor JC; Thollot F; Garcia-Corbeira P; Damaso S; Han HH; Bouckenooghe A
Vaccine; 2010 Jul; 28(32):5272-9. PubMed ID: 20538094
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.
Vesikari T; Karvonen A; Bouckenooghe A; Suryakiran PV; Smolenov I; Han HH
Vaccine; 2011 Mar; 29(11):2079-84. PubMed ID: 21238572
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.
Steele AD; Reynders J; Scholtz F; Bos P; de Beer MC; Tumbo J; Van der Merwe CF; Delem A; De Vos B
J Infect Dis; 2010 Sep; 202 Suppl():S93-100. PubMed ID: 20684724
[TBL] [Abstract][Full Text] [Related]
5. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
[TBL] [Abstract][Full Text] [Related]
6. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.
Dang DA; Nguyen VT; Vu DT; Nguyen TH; Nguyen DM; Yuhuan W; Baoming J; Nguyen DH; Le TL;
Vaccine; 2012 Apr; 30 Suppl 1():A114-21. PubMed ID: 22520120
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants.
Li RC; Huang T; Li Y; Wang LH; Tao J; Fu B; Si G; Nong Y; Mo Z; Liao X; Luan I; Tang H; Rathi N; Karkada N; Han HH
Hum Vaccin Immunother; 2016 Mar; 12(3):785-93. PubMed ID: 27149266
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
9. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines.
Steele AD; De Vos B; Tumbo J; Reynders J; Scholtz F; Bos P; de Beer MC; Van der Merwe CF; Delem A
Vaccine; 2010 Sep; 28(39):6542-8. PubMed ID: 18786585
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life.
Kawamura N; Tokoeda Y; Oshima M; Okahata H; Tsutsumi H; Van Doorn LJ; Muto H; Smolenov I; Suryakiran PV; Han HH
Vaccine; 2011 Aug; 29(37):6335-41. PubMed ID: 21640780
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.
Shin S; Anh DD; Zaman K; Yunus M; Mai le TP; Thiem VD; Azim T; Victor JC; Dallas MJ; Steele AD; Neuzil KM; Ciarlet M
Vaccine; 2012 Apr; 30 Suppl 1():A106-13. PubMed ID: 22520119
[TBL] [Abstract][Full Text] [Related]
12. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
13. A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada.
Dennehy PH;
Vaccine; 2006 May; 24(18):3780-1. PubMed ID: 16111790
[TBL] [Abstract][Full Text] [Related]
14. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa.
Steele AD; Madhi SA; Louw CE; Bos P; Tumbo JM; Werner CM; Bicer C; De Vos B; Delem A; Han HH
Pediatr Infect Dis J; 2011 Feb; 30(2):125-30. PubMed ID: 20842070
[TBL] [Abstract][Full Text] [Related]
15. Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines.
Vesikari T; Joensuu J; Baer M; Käyhty H; Olander RM; Sormunen H; Miettinen A; Ward RL; Guillot T
Acta Paediatr; 1999 May; 88(5):513-20. PubMed ID: 10426173
[TBL] [Abstract][Full Text] [Related]
16. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS
Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027
[TBL] [Abstract][Full Text] [Related]
17. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America.
Tregnaghi MW; Abate HJ; Valencia A; Lopez P; Da Silveira TR; Rivera L; Rivera Medina DM; Saez-Llorens X; Gonzalez Ayala SE; De León T; Van Doorn LJ; Pilar Rubio MD; Suryakiran PV; Casellas JM; Ortega-Barria E; Smolenov IV; Han HH;
Pediatr Infect Dis J; 2011 Jun; 30(6):e103-8. PubMed ID: 21378594
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants.
Vesikari T; Karvonen A; Korhonen T; Espo M; Lebacq E; Forster J; Zepp F; Delem A; De Vos B
Vaccine; 2004 Jul; 22(21-22):2836-42. PubMed ID: 15246619
[TBL] [Abstract][Full Text] [Related]
19. A short report on highlights of worldwide development of RIX4414: a Singaporean experience.
Phua KB; Quak SH; Emmanuel S; Goh PS; Han HH; Hardt K; Bock HL; De Vos B
Vaccine; 2006 May; 24(18):3782-3. PubMed ID: 16600443
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study.
Kim JS; Bae CW; Lee KY; Park MS; Choi YY; Kim KN; Kim JD; Park WS; Sin JB; Kim EA; Lee SG; Kim CS; Cha SH; Hong YJ; Shin SM; Shim GH; Choi KM; Yang JW; Liu A; Suryakiran PV; Han HH
Hum Vaccin Immunother; 2012 Jun; 8(6):806-12. PubMed ID: 22699440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
